The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
Friday, November 01, 2019
Vertex announced the EMA has validated the Marketing Authorization Application for the VX-445 (elexacaftor), tezacaftor and ivacaftor triple ...
read more
Thursday, October 31, 2019
ICU Medical is voluntarily recalling one single lot of Lactated Ringer's Injection, USP, and one single lot of 0.9% Sodium Chloride Injection, USP.
read more
Thursday, October 31, 2019
AbbVie announced positive top-line data from the SELECT-PsA 2 Phase 3 study.
read more
Thursday, October 31, 2019
Dicerna announced an agreement with Roche to develop novel therapies for the treatment of chronic hepatitis B virus infection.
read more
Wednesday, October 30, 2019
Q-linea announced the company has received the official response including a number of clarifications and very positive feedback from the FDA, ...
read more
Tuesday, October 29, 2019
DiscGenics has received the go-ahead from an independent DSMC to enroll the final 24 patients in its first-in-human U.S. clinical study of IDCT.
read more
VistaGen announced the EPO has granted the Company a second patent for therapeutic uses of AV-101, its oral NMDA receptor glycine site antagonist.
read more
AIVITA Biomedical has announced updated data from its ongoing glioblastoma Phase 2 clinical trial investigating AIVITA's platform immunotherapy ...
read more
Thursday, October 24, 2019
BERG announced results from a preclinical study of its investigational drug BPM 31510 (novel ubidecarenone formulation) in glioblastoma models.
read more
Wednesday, October 23, 2019
Vitalis announced its goal of commercializing its lead product candidate VTS-72 in 2021.
read more
Wednesday, October 23, 2019
Heron announced the FDA has approved Heron's sNDA for CINVANTI injectable emulsion for IV use.
read more
Tuesday, October 22, 2019
The FDA has approved Trikafta, the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation.
read more
Indalo Therapeutics announced the first IPF patient has been dosed in a clinical trial of the company's lead drug candidate IDL-2965.
read more
Seelos Therapeutics announced an amendment of the agreement with Vyera Pharmaceuticals for the development of SLS-002.
read more
ADC announced the first patients have been dosed in a Phase 2 clinical trial evaluating ADCT-301 in patients with relapsed or refractory Hodgkin ...
read more